

Michael Holinstat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/48056/publications.pdf>

Version: 2024-02-01

107
papers

4,111
citations

94269

37
h-index

118652

62
g-index

110
all docs

110
docs citations

110
times ranked

5260
citing authors

#	ARTICLE	IF	CITATIONS
1	Normal platelet function. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 195-198.	2.7	242
2	Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. <i>Blood</i> , 2014, 123, e37-e45.	0.6	199
3	RhoA Interaction with Inositol 1,4,5-Trisphosphate Receptor and Transient Receptor Potential Channel-1 Regulates Ca ²⁺ Entry. <i>Journal of Biological Chemistry</i> , 2003, 278, 33492-33500.	1.6	198
4	Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. <i>Nature Medicine</i> , 2013, 19, 1609-1616.	15.2	190
5	Functional Selectivity of G Protein Signaling by Agonist Peptides and Thrombin for the Protease-activated Receptor-1*. <i>Journal of Biological Chemistry</i> , 2005, 280, 25048-25059.	1.6	173
6	Protein Kinase C δ Phosphorylates the TRPC1 Channel and Regulates Store-operated Ca ²⁺ Entry in Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 20941-20949.	1.6	160
7	Suppression of RhoA Activity by Focal Adhesion Kinase-induced Activation of p190RhoGAP. <i>Journal of Biological Chemistry</i> , 2006, 281, 2296-2305.	1.6	150
8	Protein Kinase C δ -Induced p115RhoGEF Phosphorylation Signals Endothelial Cytoskeletal Rearrangement. <i>Journal of Biological Chemistry</i> , 2003, 278, 28793-28798.	1.6	141
9	Anti-inflammatory γ -3 endocannabinoid epoxides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6034-E6043.	3.3	136
10	Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases. <i>Pharmacological Reviews</i> , 2018, 70, 526-548.	7.1	131
11	Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. <i>Blood</i> , 2014, 124, 3450-3458.	0.6	107
12	PAR4, but Not PAR1, Signals Human Platelet Aggregation via Ca ²⁺ Mobilization and Synergistic P2Y ₁₂ Receptor Activation. <i>Journal of Biological Chemistry</i> , 2006, 281, 26665-26674.	1.6	99
13	Modulatory role of focal adhesion kinase in regulating human pulmonary arterial endothelial barrier function. <i>Journal of Physiology</i> , 2002, 539, 779-789.	1.3	83
14	Platelet 12-LOX is essential for Fc γ 3R11a-mediated platelet activation. <i>Blood</i> , 2014, 124, 2271-2279.	0.6	81
15	Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation. <i>Journal of Lipid Research</i> , 2012, 53, 2546-2559.	2.0	77
16	MicroRNA Expression Differences in Human Hematopoietic Cell Lineages Enable Regulated Transgene Expression. <i>PLoS ONE</i> , 2014, 9, e102259.	1.1	77
17	First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1828-1839.	1.1	76
18	PAR1, but Not PAR4, Activates Human Platelets through a Gi/o/Phosphoinositide-3 Kinase Signaling Axis. <i>Molecular Pharmacology</i> , 2007, 71, 1399-1406.	1.0	73

#	ARTICLE	IF	CITATIONS
19	The emerging role of oxylipins in thrombosis and diabetes. <i>Frontiers in Pharmacology</i> , 2014, 4, 176.	1.6	73
20	Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids. <i>Prostaglandins and Other Lipid Mediators</i> , 2018, 139, 10-18.	1.0	72
21	Neutrophil-Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation. <i>ACS Nano</i> , 2017, 11, 10797-10807.	7.3	71
22	The expansive role of oxylipins on platelet biology. <i>Journal of Molecular Medicine</i> , 2017, 95, 575-588.	1.7	70
23	Synthesis and Structure-Activity Relationship Studies of 4-((2-Hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 495-506.	2.9	67
24	Interaural Level Difference Processing in the Lateral Superior Olive and the Inferior Colliculus. <i>Journal of Neurophysiology</i> , 2004, 92, 289-301.	0.9	61
25	GPR56/ADGRG1 is a platelet collagen-responsive GPCR and hemostatic sensor of shear force. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28275-28286.	3.3	61
26	Rap1-Rac1 Circuits Potentiate Platelet Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 434-441.	1.1	60
27	12(S)-HETrE, a 12-Lipoxygenase Oxylipin of Dihomo- Δ^3 -Linolenic Acid, Inhibits Thrombosis via G_{12} Signaling in Platelets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2068-2077.	1.1	60
28	Discovery of Potent and Selective Inhibitors of Human Platelet-Type 12- Lipoxygenase. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5485-5497.	2.9	59
29	12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 154-164.	0.4	59
30	Protease-Activated Receptor Signaling in Platelets Activates Cytosolic Phospholipase A ₂ Differently for Cyclooxygenase-1 and 12-Lipoxygenase Catalysis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 435-442.	1.1	56
31	12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity. <i>Thrombosis and Haemostasis</i> , 2013, 110, 569-581.	1.8	54
32	Mechanism of Race-Dependent Platelet Activation Through the Protease-Activated Receptor-4 and Gq Signaling Axis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2644-2650.	1.1	50
33	Exploring deformable particles in vascular-targeted drug delivery: Softer is only sometimes better. <i>Biomaterials</i> , 2017, 124, 169-179.	5.7	45
34	Targeting 12-Lipoxygenase as a Potential Novel Antiplatelet Therapy. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 1006-1015.	4.0	45
35	Newer agents in antiplatelet therapy: a review. <i>Journal of Blood Medicine</i> , 2012, 3, 33.	0.7	42
36	Protein Kinase C Regulation of 12-Lipoxygenase-Mediated Human Platelet Activation. <i>Molecular Pharmacology</i> , 2012, 81, 420-430.	1.0	38

#	ARTICLE	IF	CITATIONS
37	Protease-Activated Receptors Differentially Regulate Human Platelet Activation through a Phosphatidic Acid-Dependent Pathway. <i>Molecular Pharmacology</i> , 2007, 71, 686-694.	1.0	37
38	15-Lipoxygenase-1 biosynthesis of 7S,14S-diHDHA implicates 15-lipoxygenase-2 in biosynthesis of resolvin D5. <i>Journal of Lipid Research</i> , 2020, 61, 1087-1103.	2.0	35
39	Role of protein kinase C η in thrombin-induced RhoA activation and inter-endothelial gap formation of human dermal microvessel endothelial cell monolayers. <i>Microvascular Research</i> , 2010, 80, 240-249.	1.1	34
40	Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1632-1643.	1.1	31
41	Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. <i>European Journal of Pharmacology</i> , 2021, 898, 173988.	1.7	31
42	Deformable microparticles for shuttling nanoparticles to the vascular wall. <i>Science Advances</i> , 2021, 7, .	4.7	28
43	Irreversible Platelet Activation Requires Protease-Activated Receptor 1-Mediated Signaling to Phosphatidylinositol Phosphates. <i>Molecular Pharmacology</i> , 2009, 76, 301-313.	1.0	27
44	12-HETE inhibits platelet reactivity and thrombosis in part through the prostacyclin receptor. <i>Blood Advances</i> , 2017, 1, 1124-1131.	2.5	26
45	PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. <i>PLoS ONE</i> , 2021, 16, e0260124.	1.1	26
46	Biosynthesis of the Maresin Intermediate, 13S,14S-Epoxy-DHA, by Human 15-Lipoxygenase and 12-Lipoxygenase and Its Regulation through Negative Allosteric Modulators. <i>Biochemistry</i> , 2020, 59, 1832-1844.	1.2	25
47	Evaluation of receptor-ligand mechanisms of dual-targeted particles to an inflamed endothelium. <i>Bioengineering and Translational Medicine</i> , 2016, 1, 103-115.	3.9	23
48	DHA 12-LOX-derived oxylipins regulate platelet activation and thrombus formation through a PKA-dependent signaling pathway. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 839-851.	1.9	23
49	5 <i>S</i> ,15 <i>S</i> -Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a Lipoxin Intermediate: Reactivity and Kinetics with Human Leukocyte 5-Lipoxygenase, Platelet 12-Lipoxygenase, and Reticulocyte 15-Lipoxygenase-1. <i>Biochemistry</i> , 2018, 57, 6726-6734.	1.2	22
50	Characterization of hemostasis in mice lacking the novel thrombosis susceptibility gene <i>Slc44a2</i> . <i>Thrombosis Research</i> , 2018, 171, 155-159.	0.8	20
51	<i>In Vitro</i> Biosynthetic Pathway Investigations of Neuroprotectin D1 (NPD1) and Protectin DX (PDX) by Human 12-Lipoxygenase, 15-Lipoxygenase-1, and 15-Lipoxygenase-2. <i>Biochemistry</i> , 2021, 60, 1741-1754.	1.2	20
52	In vivo modeling of docosahexaenoic acid and eicosapentaenoic acid-mediated inhibition of both platelet function and accumulation in arterial thrombi. <i>Platelets</i> , 2019, 30, 271-279.	1.1	17
53	Omega-6 DPA and its 12-lipoxygenase-oxidized lipids regulate platelet reactivity in a nongenomic PPAR α -dependent manner. <i>Blood Advances</i> , 2020, 4, 4522-4537.	2.5	17
54	Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish. <i>Blood Advances</i> , 2018, 2, 3418-3427.	2.5	16

#	ARTICLE	IF	CITATIONS
55	KLF11 (KrÄppel-Like Factor 11) Inhibits Arterial Thrombosis via Suppression of Tissue Factor in the Vascular Wall. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 402-412.	1.1	15
56	Modified two-step emulsion solvent evaporation technique for fabricating biodegradable rod-shaped particles in the submicron size range. <i>Journal of Colloid and Interface Science</i> , 2018, 518, 174-183.	5.0	14
57	Role of Human 15-Lipoxygenase-2 in the Biosynthesis of the Lipoxin Intermediate, 5S,15S-diHpETE, Implicated with the Altered Positional Specificity of Human 15-Lipoxygenase-1. <i>Biochemistry</i> , 2020, 59, 4118-4130.	1.2	14
58	A new way to treat proximal deep venous thrombosis using E-selectin inhibition. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 268-278.	0.9	14
59	Development of Poly Unsaturated Fatty Acid Derivatives of Aspirin for Inhibition of Platelet Function. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 359, 134-141.	1.3	13
60	12-HETrE, An Endogenous Inhibitor of Platelet Activation,. <i>Blood</i> , 2011, 118, 3254-3254.	0.6	12
61	Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice. <i>Science Advances</i> , 2020, 6, .	4.7	11
62	Antisense oligonucleotides and nucleic acids generate hypersensitive platelets. <i>Thrombosis Research</i> , 2021, 200, 64-71.	0.8	11
63	Identification of a Racially Dimorphic Variant in the Human Platelet PAR4 Thrombin Receptor Altering Platelet Function and Pharmacologic Inhibition. <i>Blood</i> , 2014, 124, 1434-1434.	0.6	11
64	Who is the real 12-HETrE?. <i>Prostaglandins and Other Lipid Mediators</i> , 2017, 132, 25-30.	1.0	9
65	Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1817-1830.	1.1	9
66	Protease Activated Receptors Differentially Regulate Human Platelet Activation through Phosphatidic Acid-Dependent DAG Formation.. <i>Blood</i> , 2006, 108, 3906-3906.	0.6	7
67	Identification of the Genetic Mechanism Responsible for Racially-Dimorphic Expression of the Thrombin-Receptor Regulator, Pctp. <i>Blood</i> , 2015, 126, 415-415.	0.6	7
68	Defibrotide Therapy for SARS-CoV-2 ARDS. <i>Chest</i> , 2022, 162, 346-355.	0.4	7
69	Pharmacologic targeting of Cdc42 GTPase by a small molecule Cdc42 activity-specific inhibitor prevents platelet activation and thrombosis. <i>Scientific Reports</i> , 2021, 11, 13170.	1.6	6
70	Supplementation with omegaâ or omegaâ fatty acids attenuates platelet reactivity in postmenopausal women. <i>Clinical and Translational Science</i> , 2022, 15, 2378-2391.	1.5	6
71	We Can Do It Together: PAR1/PAR2 Heterodimer Signaling in VSMCs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2775-2776.	1.1	5
72	Identification of a functional genetic variant driving racially dimorphic platelet gene expression of the thrombin receptor regulator, PCTP. <i>Thrombosis and Haemostasis</i> , 2017, 117, 962-970.	1.8	5

#	ARTICLE	IF	CITATIONS
73	E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 211-220.	0.9	5
74	Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 209-222.	1.0	4
75	Racial Differences in Resistance to P2Y ₁₂ Receptor Antagonists in Type 2 Diabetic Subjects. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 33-43.	1.3	4
76	Resolvin the clot: DVT resolution through RvD4. <i>Blood</i> , 2019, 134, 1370-1371.	0.6	4
77	Coronary Heart Disease Risk Factors Take a Disproportional Toll on Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 750-751.	1.1	2
78	Dual antiplatelet therapy for PCI: Are we tailored to all?. <i>Thrombosis Research</i> , 2015, 135, 1045-1046.	0.8	2
79	Complement factors (H) into thrombosis. <i>Blood</i> , 2017, 129, 1065-1066.	0.6	2
80	Controlling the Clot: ANXA7 Regulates Collagen Activation of Platelet Through 12-LOX. <i>Circulation Research</i> , 2021, 129, 508-510.	2.0	2
81	New LINE(s) of Evidence for Genetic Regulation of Platelets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 690-691.	1.1	1
82	Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110185.	0.7	1
83	A Large Cluster of Micrnas At 14q32 Defines an RNA Expression Module That Accounts for Racial Differences in Protease Activated Receptor 4-Mediated Platelet Reactivity. <i>Blood</i> , 2012, 120, 380-380.	0.6	1
84	Novel 12-LOX Inhibitor ML355 Attenuates Platelet Reactivity and Impairs Thrombus Growth, Stability and Vessel Occlusion In Vivo. <i>Blood</i> , 2015, 126, 3442-3442.	0.6	1
85	Role of 12-LOX in the Platelet Storage Lesion. <i>Blood</i> , 2021, 138, 3241-3241.	0.6	1
86	Protein kinase C δ phosphorylates the TRPC1 channel and regulates store-operated Ca ²⁺ entry in endothelial cells.. <i>Journal of Biological Chemistry</i> , 2011, 286, 36162.	1.6	0
87	Popping the lid on PAR4 activation. <i>Blood</i> , 2020, 136, 2101-2102.	0.6	0
88	PI3K differentially regulates protease activated receptor-mediated platelet activation in humans through Rap1. <i>FASEB Journal</i> , 2007, 21, A603.	0.2	0
89	Irreversible Platelet Activation Requires PAR1 Regulation of Phosphatidylinositol Phosphates (PIPns) Activation of Rap1.. <i>Blood</i> , 2007, 110, 3889-3889.	0.6	0
90	PAR1-mediated stable platelet aggregation requires temporal regulation of Rap1 activity by phosphatidylinositol phosphates (PIPns).. <i>FASEB Journal</i> , 2008, 22, 646.3.	0.2	0

#	ARTICLE	IF	CITATIONS
91	12-Lipoxygenase plays a significant role in regulation of human platelets activation. FASEB Journal, 2010, 24, 574.4.	0.2	0
92	Platelet 12-Lipoxygenase Is Required for Dense Granule Secretion and Platelet Aggregation: Role of 12-hLO In Platelet Hemostasis and Thrombosis. Blood, 2010, 116, 3203-3203.	0.6	0
93	Altered platelet reactivity in humans diagnosed with type 2 diabetes mellitus. FASEB Journal, 2011, 25, 1089.5.	0.2	0
94	Protein kinase C regulates agonist-mediated platelet activation downstream of 12-Lipoxygenase in human platelets. FASEB Journal, 2011, 25, 1089.1.	0.2	0
95	Differential signaling of PAR1 and PAR4 through 12-hLO. FASEB Journal, 2011, 25, 1009.6.	0.2	0
96	The regulation of thrombosis and hemostasis by fatty acid metabolites. FASEB Journal, 2012, 26, 991.1.	0.2	0
97	An ω -6 Fatty Acid, Dgla, Prevents Platelet Activation and Thrombosis in Vivo.. Blood, 2012, 120, 2169-2169.	0.6	0
98	Racial Differences In Thrombin-Induced Human Platelet PAR4 Reactivity. Blood, 2013, 122, 1054-1054.	0.6	0
99	Effect Of Age and Gender On Human Platelet mRNA and Micro-RNA Levels. Blood, 2013, 122, 3518-3518.	0.6	0
100	PAR4 Mediates an Elevated Risk for Thrombosis in Blacks Relative to Whites (LB602). FASEB Journal, 2014, 28, LB602.	0.2	0
101	12-HETrE, a Novel 12-LOX Oxylipin, Prevents Platelet Activation in a $G_{i\pm s}$ -like Manner. Blood, 2014, 124, 1436-1436.	0.6	0
102	Pharmacogenocis of PAR4: PAR4 Polymorphism Determines Platelet Response in the Presence of Dual Anti-Platelet Therapy. Blood, 2015, 126, 3446-3446.	0.6	0
103	The Common PAR4 Ala120Thr Variant Has a Major Effect on Platelet Reactivity to Thrombin and These Effects Are Enhanced with PAR1 and P2Y12 Inhibition. Blood, 2016, 128, 709-709.	0.6	0
104	Potent Anti-Platelet Metabolite, 12-HETrE, Inhibits Platelet Activation and Thrombosis In Vivo Via Activation of the IP Receptor. Blood, 2016, 128, 714-714.	0.6	0
105	The Antithrombotic Effects of 12-LOX Derived Metabolites of DPA, ω -6. FASEB Journal, 2018, 32, 571.5.	0.2	0
106	Mitigation of SARS-CoV2-Mediated Endothelial Injury via Suppression of the Epigenetic Enzyme KMT2A/MLL1 in Macrophages. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 541-543.	0.9	0
107	207 Omega-3 and omega-6 fatty acids attenuate platelet reactivity in postmenopausal women. Journal of Clinical and Translational Science, 2022, 6, 31-32.	0.3	0